P
Pi-Cardia
A medical device start-up company developing a novel low profile catheter for the treatment of Aortic Stenosis
About Pi-Cardia
Pi-Cardia is a medical device company specializing in non-implant based treatments for aortic valve repair. The company's core product, the Leaflex Performer, is designed to treat calcified aortic valves by creating scoring lines that separate calcium deposits, thereby increasing leaflet flexibility and improving valve hemodynamics. This unique mechanism aims to enhance the aortic valve area without the need for implants, offering a less invasive alternative to traditional valve replacement surgeries. Pi-Cardia primarily serves the cardiovascular healthcare market, targeting patients with aortic stenosis, a condition characterized by the narrowing of the aortic valve opening due to calcification. The business model revolves around the development, clinical testing, and eventual commercialization of its proprietary technology. Revenue is generated through the sale of the Leaflex Performer device to hospitals and healthcare providers. The company operates in a highly specialized segment of the medical device industry, focusing on innovative solutions that reduce procedure time, hospitalization duration, and overall healthcare costs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Rehovot, Israel
- Employees
- 90
- Open positions
- 19
- Dealroom signal
- 90.6/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Cardiology and cardiovascular, Catheters, Valves, Soft Tissues, Surgical Equipment, Tech for Hospitals and Clinics, Hard Tech, DT and LS
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Sep 2026 | $80M | $320M | Sofinnova Partners · SPRIG Equity · Jacques R. Seguin · Medtronic | ↗ |
| DEBTDebt | Jan 2021 | $21M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Pi-Cardia is 3K monthly website visits, up 257.1% over the last three months. Pi-Cardia's team grew 32.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Anges Quebec
Innogest Capital
Series B and later6 investors entered at this stage
Atlante Ventures
Clal Biotechnology Industries
Sofinnova Partners
Medtronic
SPRIG Equity
Jacques R. Seguin
Other known investors3 additional known investors
Claudio Rumazza
Indaco Venture Partners- JPJVC Investment Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pi-Cardia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pi-Cardia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.